Send us Feedback

Hemispherx BioPharma (HEB)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
An Outrageous, Shameless Act by Hemispherx's Board of Directors
TheStreet.com  May 1  Comment 
PHILADELPHIA (TheStreet) -- Hemispherx Biopharma's board of directors committed the most egregious act of shareholder fleecing I've ever come across. My mouth is agape, in bewilderment, as I type this: Chief executive officer Bill Carter was...
Hemispherx Wins Broad Treatment Expansion for Alferon N Injection in Argentina
Benzinga  Mar 4  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and...
Notable 52-Week Highs and Lows of the Day 02/05: (NFLX) (ETN) (CSC) High; (HEB) Low
StreetInsider.com  Feb 5  Comment 
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High: Netflix (Nasdaq: NFLX) $177.89. Murmurs that Netflix might be next in line for Nasdaq-100 inclusion have...
Hemispherx's Ampligen odyssey ends with (another) FDA rejection
FierceBiotech  Feb 5  Comment 
Five years after filing for an approval of the chronic fatigue syndrome drug Ampligen, the FDA has spurned the application again, asking for additional information and another clinical trial. Hemispherx ($HEB) said it is planning a formal appeal,...
StreetInsider.com Pre-Open Movers 02/05: (OPXA) (PLX) (VMED) Higher; (HEB) (YUM) (JCP) Lower (more...)
StreetInsider.com  Feb 5  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA) 300% HIGHER; announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna (imilecleucel-T), a potential...
Hemispherx (HEB) Updates on FDA Panel Vote for Ampligen; Fails to Win Backing
StreetInsider.com  Dec 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+%28HEB%29+Updates+on+FDA+Panel+Vote+for+Ampligen%3B+Fails+to+Win+Backing/7967322.html for the full story.
Hemispherx Biopharma Says FDA Panel Voted 9-4 Against Ampligen Effocacy
Benzinga  Dec 21  Comment 
Unusual 11 Mid-Day Movers 12/21: (HALO) (ASCA) (FCFC) Higher; (HEB) (EDMC) (RIMM) Lower
StreetInsider.com  Dec 21  Comment 
Halozyme Therapeutics, Inc. (Nasdaq: HALO) 28.6% HIGHER; Halozyme entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (NYSE: PFE) for the purpose of developing and commercializing products combining proprietary Pfizer...
StreetInsider.com Pre-Open Movers 12/21: (ASCA) (RHT) (NKE) Higher; (HEB) (ECTE) (RIMM) Lower (more...)
StreetInsider.com  Dec 21  Comment 
[$] Panel Rejects Drug for Chronic Fatigue Syndrome
Wall Street Journal  Dec 20  Comment 
A federal advisory panel said a proposed medicine from Hemispherx Biopharma Inc. to treat chronic fatigue syndrome isn't ready for approval.
Hemispherx BioPharma Soars Then Plunges as FDA Panel Votes Against Ampligen Approval
Benzinga  Dec 20  Comment 
FDA Panel Nixes Hemispherx CFS Drug
MedPage Today  Dec 20  Comment 
StreetInsider.com After-Hours Movers 12/20: (RHT) (NKE) (RIMM) Higher; (HEB) (MU) Lower (more...)
StreetInsider.com  Dec 20  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) 22% LOWER; fails to win FDA panel backing for Ampligen efficacy Red Hat, Inc. (NYSE: RHT) 6% HIGHER; reported Q3 EPS of $0.29, in-line with the analyst estimate of $0.29. Revenue for the quarter came in at...




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Hemispherx BioPharma (HEB):

 
TOP CONTRIBUTORS
Associate
James W Miller
 Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.



References

http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Retrieved from "http://www.wikinvest.com/stock/Hemispherx_BioPharma_(HEB)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki